Characteristics of PAH Patients Treated Initially with Parenteral Prostanoids Differ from Those Treated Initially with Oral Therapy Despite Matching for REVEAL Risk Score
Frantz, R.P, Farber, H.W, Miller, D.P, Benton, W.W, McGoon, M.D
Published in The Journal of heart and lung transplantation (01.04.2013)
Published in The Journal of heart and lung transplantation (01.04.2013)
Get full text
Journal Article
The PROSPECT Registry of Pulmonary Arterial Hypertension (PAH): Description of Patients Who Transitioned From Inhaled Prostacyclin to Intravenous Epoprostenol
Farber, H.W, Frantz, R.P, Schilz, R.J, Chin, K, Rosenberg, D, Colvin, J, Hartline, B.K, Miller, D.P, Benton, W.W, Chakinala, M
Published in The Journal of heart and lung transplantation (01.04.2014)
Published in The Journal of heart and lung transplantation (01.04.2014)
Get full text
Journal Article
PROSPECT Patient Subgroups and Etiologies: Predictors of Outcomes
Schilz, R.O, Badesch, D.B, Barst, R.J, Chakinala, M, Frantz, R.P, Miller, D.P, Hartline, B.K, Benton, W.W, McLaughlin, V.V, Farber, H.W
Published in The Journal of heart and lung transplantation (01.04.2013)
Published in The Journal of heart and lung transplantation (01.04.2013)
Get full text
Journal Article
56 Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension
Chin, K.M, Badesch, D.B, Robbins, I.M, Tapson, V.F, Palevsky, H, Kim, N.H, Kawut, S.M, Frost, A, Benton, W.W, Lemarie, J.C, Bodin, F, Rubin, L.J, McLaughlin, V.V
Published in The Journal of heart and lung transplantation (01.04.2012)
Published in The Journal of heart and lung transplantation (01.04.2012)
Get full text
Journal Article